AHA Guidelines On vs CardioGenetics

Access guidelines on your mobile device anytime, anywhere! Download the American Heart Association mobile app today and enjoy the benefits of staying up-to-date no matter where you are. Effective integration of complex clinical treatment guidelines, tagged and mapped for effective search with cross-linking, resources and more. Additional guidelines will be added soon! Disclaimer: The clinical guidelines, care pathways, and other clinical guidance and recommendations presented in the AHA on-the-go Guidelines App were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The results and recommendations provided in this application do not replace clinical judgment of the care provider. Therapeutic options should be individualized and determined after discussion between the patient and their care provider.

Every inherited cardiomyopathy evaluation warrants meticulous, accurate, and evidence-based risk stratification. CardioGenetics compiles validated calculators, diagnostic frameworks, and a live clinical trial finder in your pocket. USED AT THE BEDSIDE Whether you are presenting at a multidisciplinary cardiomyopathy board, interpreting a new pathogenic variant, or seeing your first LMNA patient, CardioGenetics gives the same tools with the evidence and models behind every number. ASCVD RISK ALIGNED WITH THE 2026 GUIDELINES Calculate 10-year risk with AHA PREVENT (ages 30–79), compare against the legacy Pooled Cohort Equations, integrate coronary artery calcium via the MESA score, and interpret Lipoprotein(a) with a built-in risk multiplier. Every result maps directly to the 2026 ACC/AHA dyslipidemia guideline statin thresholds, risk-enhancing factors, and CAC decision pathways. GENE-SPECIFIC SUDDEN CARDIAC DEATH RISK Not all cardiomyopathies carry the same arrhythmic risk. CardioGenetics includes dedicated calculators for HCM (ESC 2014 Risk-SCD), ARVC (Cadrin-Tourigny), LMNA (Wahbi, ESC 2023-adapted), PLN p.Arg14del (Verstraelen), DSP (ERADOS, Eur Heart J 2024), FLNC (Gigli, JAMA Cardiol 2025), and PKP2-specific guidance. Each cross-referenced to the latest ESC 2023 and AHA/ACC 2024 guidelines. DIAGNOSTIC FRAMEWORKS AT YOUR FINGERTIPS Confirm diagnoses before you risk-stratify. Built-in criteria include the 2020 Padua Criteria for arrhythmogenic cardiomyopathy, AHA/ACC 2024 and ESC 2023 HCM diagnostic standards, LVNC scoring (Jenni, Petersen, Stöllberger), and DCM phenotyping. FIND THE RIGHT CLINICAL TRIAL Browse actively enrolling studies for Lp(a), HCM, ACM/ARVC, DSP, LMNA, and PLN with interactive U.S. state and European enrollment maps. Every trial includes its NCT identifier and a direct link to ClinicalTrials.gov. DESIGNED FOR WHAT WE ACTUALLY DO IN CLINIC • Search any calculator, diagnosis, or trial from a single search bar • Tap a risk score and see the full mathematical model, original citation, and DOI • View sensitivity analyses and interactive risk curves • Share lay-language summaries during patient-facing discussions • Cross-navigate between diagnostic confirmation and risk stratification in one tap TRUST BUT VERIFY: Every calculator reproduces its published equation with full variable definitions and baseline coefficients. There are no "black boxes" here, no proprietary modifications. Tap any citation to access the original published manuscript. INTENDED USERS: Cardiologists · Electrophysiologists · Genetic Counselors · Cardiology Fellows and Residents · Medical Students · Advanced Practice Providers · Inherited Cardiovascular Disease Teams Developed by Mark E. Pepin, MD, PhD, FESC. All risk models are derived from peer-reviewed literature and their original sources. This app is a clinical decision-support aid for healthcare professionals and does not replace clinical judgment, institutional protocols, or shared decision-making. Not FDA-cleared or CE-marked.